Cytek Q2 2026 Earnings: Revenue Rose 6% as Losses Widened

Cytek Biosciences (Nasdaq: CTKB) reported Q2 2026 revenue of $48.1 million, up 6% from $45.6 million a year earlier, while diluted GAAP EPS was -$0.09 versus -$0.04. Reported GAAP gross margin rose to 59%, but a one-time tariff refund accounted for most of the expansion; excluding the refund, margin was 53%. Instrument growth in the U.S. and China and higher service revenue supported sales, while faster expense growth and weaker non-operating results widened the net loss.

Core Earnings Data

Revenue increased by $2.5 million year over year, driven by instrument growth in the U.S. and China and continued service expansion. However, operating expenses rose 15%, outpacing revenue growth and preventing the higher gross profit from improving operating results.

Business and Recurring Revenue Performance

Product revenue increased about 4% to $32.6 million, while service revenue grew about 10% to $15.6 million. Management attributed overall growth to strong double-digit instrument revenue growth in both the U.S. and China, together with continued service expansion.

Recurring revenue, consisting of service and reagent sales, reached $18.5 million during the quarter. On a trailing-12-month basis, recurring revenue represented 35% of total revenue, up from 32% a year earlier. This mix shift provides a larger recurring component, although most revenue still comes from outside the service and reagent category.

Cytek added 142 instruments during the quarter, bringing its installed base to 3,933. The company also launched the seven-laser Cytek Borealis system and introduced Aurora Evo configurations with expanded automation capabilities. Management identified adoption of these platforms and further recurring-revenue expansion as strategic priorities, but it did not quantify the new products’ Q2 revenue contribution.

A Tariff Refund Lifted Gross Margin, but Expense Growth Kept Profitability Under Pressure

The reported margin increase requires an important adjustment. Excluding the one-time tariff refund, GAAP gross margin would have been 53%, compared with the reported 59% and 52% in Q2 2025. Similarly, adjusted gross margin would have been 56% without the refund—unchanged from a year earlier—rather than the reported 61%.

Gross profit increased by about $4.5 million, but operating expenses rose by approximately $5.2 million. Research and development expense increased 10% to $9.7 million, sales and marketing expense rose 9% to $13.2 million, and general and administrative expense increased 24% to $16.8 million. Cytek attributed the G&A increase to litigation-related expenses, severance, and personnel costs.

The net loss deteriorated more sharply than the operating loss. Total other income and expense moved from $3.8 million of income in Q2 2025 to $0.2 million of expense, while a $1.2 million income-tax benefit became a $0.5 million tax provision. Adjusted EBITDA also moved from a $1.3 million profit to a $1.5 million loss, indicating that the profitability pressure was not limited to GAAP non-operating items.

Liquidity and Balance Sheet

Cash, cash equivalents, and marketable securities totaled $262.0 million on June 30, 2026, nearly unchanged from $262.2 million on March 31. Long-term debt was $0.2 million at quarter-end.

Compared with December 31, 2025, accounts receivable declined to $49.7 million from $62.5 million, while inventory increased to $52.3 million from $48.4 million. The inventory increase is a working-capital item to monitor as Cytek seeks to accelerate instrument adoption during the remainder of the year.

Full-Year Guidance

Cytek updated its fiscal 2026 revenue outlook and raised the midpoint by $1 million. The guidance assumes no change in current foreign-exchange rates.

The new range has a midpoint of about $209.5 million. With first-half revenue of $92.3 million, the outlook implies approximately $114.7 million to $119.7 million of second-half revenue, placing meaningful weight on increased sales during the remainder of 2026.

Risks Investors Should Monitor

• Gross-margin normalization: The tariff refund added six percentage points to reported GAAP gross margin. Without another similar benefit, future reported margins may be lower even if underlying operations remain stable.
• Expense growth and continued losses: Operating expenses grew faster than revenue, and adjusted EBITDA turned negative. Litigation, severance, personnel spending, and investment in product commercialization could continue to pressure profitability.
• Execution against second-half guidance: Reaching the full-year range requires second-half revenue to exceed first-half revenue materially. Results will depend in part on instrument demand and adoption of recently launched platforms.
• Policy, tariff, and currency exposure: Cytek identified export controls, tariffs, NIH funding policies, and foreign-exchange movements as factors that could affect demand, costs, and its outlook. The current guidance specifically assumes stable exchange rates.

Summary

Cytek’s Q2 2026 results showed moderate revenue growth, a larger recurring-revenue mix, and continued installed-base expansion. However, the headline gross-margin improvement depended heavily on a one-time tariff refund, while operating expenses outgrew revenue and adjusted EBITDA turned negative. The main items to watch are new-platform adoption, expense control, normalized margins, and whether second-half revenue can support the updated full-year guidance.